The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Cozac V.V.

Hospital of the University of Basel, Basel, Switzerland

Determining the risk of dementia in Parkinson’s disease: possibilities and perspectives

Authors:

Cozac V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(6): 137‑143

DOI: 10.17116/jnevro2019119061137

Read: 1593 times

Download PDF (RU)
Contact the author
Table of contents

DETERMINING THE RISK OF DEMENTIA IN PARKINSON’S DISEASE: POSSIBILITIES AND PERSPECTIVES
DETERMINING THE RISK OF DEMENTIA IN PARKINSON’S DISEASE: POSSIBILITIES AND PERSPECTIVES

To cite this article:

Cozac VV. Determining the risk of dementia in Parkinson’s disease: possibilities and perspectives. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(6):137‑143. (In Russ.)
https://doi.org/10.17116/jnevro2019119061137

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Labo­ratory biomarkers for the prognosis of chro­nic heart failure. Labo­ratory Service. 2024;(3):5-16
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
Abstract:

Dementia in Parkinson’s disease (D-PD) worsens the course of PD, and it is associated with a decrease in the quality of life of patients and caregivers, as well as with elevated costs for patient care, and, as a consequence, leads to a significant cost increase in the health management. Early detection of the risk of dementia in patients with PD is one of the challenges of modern clinical neurology. Various methods for the detection of morphologic and functional changes associated with D-PD risk (prognostic biomarkers) were suggested. The aim of this article is a brief review of current achievements in the search for and evaluation of the effectiveness of such biomarkers. The review included the following methods: clinical examination, neuroimaging, examination of biological fluids, genetic analysis, neurophysiological methods and combined methods. Biomarkers of D-PD can contribute to optimization of the selection of pharmacological or non-pharmacological methods of preventing cognitive impairment at early stages of PD, and, therefore, to potential improvement of the overall clinical outcomes.

Keywords:

dementia
Parkinson’s disease
biomarkers

Authors:

Cozac V.V.

Hospital of the University of Basel, Basel, Switzerland

Close metadata

References:

  1. Capriotti T, Terzakis K. Parkinson Disease. Home Healthcare Now. 2016;34(6):300-307. https://doi.org/10.1097/NHH.0000000000000398
  2. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Movement Disorders. 2014;29:1583-1590. https://doi.org/10.1002/mds.25945
  3. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276-281. https://doi.org/10.1212/WNL.0b013e31827deb74
  4. Aarsland D, Creese B, Politis M, Chaudhuri KR, ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nature Reviews Neurology. 2017;13:217-231. https://doi.org/10.1038/nrneurol.2017.27
  5. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. Brain Pathology. 2010;20:633-639. https://doi.org/10.1111/j.1750-3639.2009.00369.x
  6. Kim JW, Cheon SM, Park MJ, Kim SY, Jo HY. Cognitive impairment in Parkinson’s disease without dementia: subtypes and influences of age. Journal of Clinical Neurology. 2009;5(3):133-138. https://doi.org/10.3988/jcn.2009.5.3.133
  7. Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU. Journal of Clinical Neurology. 2009;5(3):133-138. https://doi.org/10.1007/s00415-008-0720-2
  8. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Movement Disorders. 2005;20:1255-1263. https://doi.org/10.1002/mds.20527
  9. Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Pezzella D, di Grazia A, Erro R, Pellecchia MT, Amboni M, Trojano L, Barone P. Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism and Related Disorders. 2015;21:1219-1226. https://doi.org/10.1016/j.parkreldis.2015.08.024
  10. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurology. 2013;70:580-586. https://doi.org/10.1001/jamaneurol.2013.2110
  11. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;84:1258-1264. https://doi.org/10.1136/jnnp-2013-305277
  12. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23:837-844. https://doi.org/10.1002/mds.21956
  13. Levy G, Tang MX, Louis ED, Côté LJ, Alfaro B, Mejia H, Stern Y, Marder K. The association of incident dementia with mortality in PD. Neurology. 2002;59(11):1708-1713. https://doi.org/10.1212/01.WNL.0000036610.36834.E0
  14. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurology. 2012;11:697-707. https://doi.org/10.1016/S1474-4422(12)70152-7
  15. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. Journal of Neurology, Neurosurgery and Psychiatry. 2007;78(1):36-42. https://doi.org/10.1136/jnnp.2005.083113
  16. Vossius C, Larsen JP, Janvin C, Aarsland D. The Economic Impact of Cognitive Impairment in Parkinson’s Disease. Movement Disorders. 2011;26(8):1541-1544. https://doi.org/10.1002/mds.23661
  17. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson’s disease? Movement Disorders. 2014;29(5):622-633. https://doi.org/10.1002/mds.25846
  18. WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. 2001. Retrieved from http://www.inchem.org/documents/ehc/ehc/ehc222.htm
  19. Amur S, LaVange L, Zineh I, Buckman‐Garner S, Woodcock J. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. Clinical Pharmacology & Therapeutics. 2015;98(1):34-46. https://doi.org/10.1002/cpt.136
  20. Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sørensen P, Marder K. The effect of age of onset of PD on risk of dementia. Journal of Neurology. 2007(b);254:38-45. https://doi.org/10.1007/s00415-006-0234-8
  21. Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K. Motor impairment in PD: relationship to incident dementia and age. Neurology. 2000;55:539-544. https://doi.org/10.1212/WNL.55.4.539
  22. Ye BS, Jeon S, Ham JH, Lee JJ, Lee JM, Lee HS, Lee PH, Sohn YH. Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. Dementia and Geriatric Cognitive Disorders. 2017;44:203-212. https://doi.org/10.1159/000479057
  23. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605-1611. https://doi.org/10.1212/01.wnl.0000242630.52203.8f
  24. Boot BP, Boeve BF, Roberts RO, Ferman TJ, Yonas E.G., Shane Pankratz V, Ivnik RJ, Smith GE, McDade E, Christianson TJH, Knopman DS, Tangalos EG, Silber MH, Petersen RC. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Annals of Neurology. 2012;71:49-56. https://doi.org/10.1002/ana.22655
  25. Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S, Hasegawa T, Sugeno N, Konno M, Suzuki K, Takahashi S, Fukuda H, Aoki M, Itoyama Y, Mori E, Takeda A. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: a 3 year longitudinal study. Brain. 2012;135:161-169. https://doi.org/10.1093/brain/awr321
  26. Anang JB, Gagnon JF, Bertrand JA, Rios Romenets S, Latreille V, Panisset M, Montplaisir J, Postuma RB. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology. 2014;83(14):1253-1260. https://doi.org/10.1212/WNL.0000000000000842
  27. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ. Grey matter atrophy in cognitively impaired Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry. 2012;83(2):188-194. https://doi.org/10.1136/jnnp-2011-300828
  28. Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, Valldeoriola F, Muñoz E, Camara A, Buongiorno M, Martí MJ. Grey matter volume correlates of cerebrospinal markers of Alzheimer pathology in Parkinson’s disease and related dementia. Parkinsonism and Related Disorders. 2012;18:941-947. https://doi.org/10.1016/j.parkreldis.2012.04.028
  29. Zarei M, Ibarretxe-Bilbao N, Compta Y, Hough M, Junque C, Bargallo N, Tolosa E, Martí MJ. Cortical thinning is associated with disease stages and dementia in Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry. 2013;84:875-881. https://doi.org/10.1136/jnnp-2012-304126
  30. Lee SJ, Kim JS, Yoo JY, Song IU, Kim BS, Jung SL, Yang DW, Kim YI, Jeong DS, Lee KS. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Disease & Associated Disorders. 2010;24:227-233. https://doi.org/10.1097/WAD.0b013e3181d71a13
  31. Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, Sato R, Sakai K, Mizusawa H. Cognitive status correlates with white matter alteration in Parkinson’s disease. Human Brain Mapping. 2012;33:727-739. https://doi.org/10.1002/hbm.21245
  32. Le Heron CJ, Wright SL, Melzer TR, Myall DJ, MacAskill MR, Livingston L, Keenan RJ, Watts R, Dalrymple-Alford JC, Anderson TJ. Comparing cerebral perfusion in Alzheimer’s disease and Parkinson’s disease dementia: an ASL-MRI study. Journal of Cerebral Blood Flow & Metabolism. 2014;34:964-970. https://doi.org/10.1038/jcbfm.2014.40
  33. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. Journal of Nuclear Medicine. 2011;52(6):848-855. https://doi.org/10.2967/jnumed.111.089946
  34. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives of Neurology. 2003;60:1745-1748. https://doi.org/10.1001/archneur.60.12.1745
  35. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80:85-91. https://doi.org/10.1212/WNL.0b013e31827b1a07
  36. Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, Sperling R, Growdon JH, Dickerson BC, Johnson K. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurology. 2016;73(11):1334-1341. https://doi.org/10.1001/jamaneurol.2016.3338
  37. Nobili F, Abbruzzese G, Morbelli S, Marchese R, Girtler N, Dessi B, Brugnolo A, Canepa C, Drosos GC, Sambuceti G, Rodriguez G. Amnestic mild cognitive impairment in Parkinson’s disease: a brain perfusion SPECT study. Movement Disorders. 2009;24:414-421. https://doi.org/10.1002/mds.22381
  38. Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain. 2012;135:2798-2808. https://doi.org/10.1093/brain/aws211
  39. Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Movement Disorders. 2009;24:2203-2210. https://doi.org/10.1002/mds.22594
  40. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055-1061. https://doi.org/10.1212/WNL.0b013e3181f39a78
  41. Sako W, Murakami N, Izumi Y, Kaji R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Movement Disorders. 2014;29(13):1599-1605. https://doi.org/10.1002/mds.26036
  42. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J, Parkinson Study Group DATATOP Investigators. Cerebrospinal fluid a-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. American Journal of Pathology. 2014;184:966-975. https://doi.org/10.1016/j.ajpath.2013.12.007
  43. Compta Y, Pereira JB, Ríos J, Ibarretxe-Bilbao N, Junqué C, Bargalló N, Cámara A, Buongiorno M, Fernández M, Pont-Sunyer C, Martí MJ. Combined dementia-risk biomarkers in Parkinson’s disease: a prospective longitudinal study. Parkinsonism and Related Disorders. 2013;19:717-724. https://doi.org/10.1016/j.parkreldis.2013.03.009
  44. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology. 2011;69:655-663. https://doi.org/10.1002/ana.22271
  45. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson’s disease. Psychosomatics. 2010;51:474-479. https://doi.org/10.1176/appi.psy.51.6.474
  46. Collins LM, Williams-Gray CH. The Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease. Frontiers in Psychiatry. 2016;7:89. https://doi.org/10.3389/fpsyt.2016.00089
  47. Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP. Cognitive profile of LRRK2 related Parkinson’s disease. Movement Disorders. 2015;30:728-733. https://doi.org/10.1002/mds.26161
  48. Ben Sassi S, Nabli F, Hentati E, Nahdi H, Trabelsi M, Ben Ayed H, Amouri R, Duda JE, Farrer MJ, Hentati F. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease. Parkinsonism & Related Disorders. 2012;18:243-246. https://doi.org/10.1016/j.parkreldis.2011.10.009
  49. Somme JH, Gomez-Esteban JC, Molano A, Tijero B, Lezcano E, Zarranz JJ. Initial neuropsychological impairments in patients with the E46K mutation of the α-synuclein gene (PARK 1). Journal of the Neurological Sciences. 2011;310:86-89. https://doi.org/10.1016/j.jns.2011.07.047
  50. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP. APOE. MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurology. 2014;71:1405-1412. https://doi.org/10.1001/jamaneurol.2014.1455
  51. Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D. GBA-associated Parkinson’s disease: reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders. 2014;30:407-411. https://doi.org/10.1002/mds.26071
  52. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958-2969. https://doi.org/10.1093/brain/awp245
  53. Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A. Genetic influences on cognitive decline in Parkinson’s disease. Movement Disorders. 2012;27:512-518. https://doi.org/10.1002/mds.24946
  54. Klassen BT, Hentz JG, Shill HA, Driver-Dunckley E, Evidente VG, Sabbagh MN, Adler CH, Caviness JN. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology. 2011;77(2):118-124. https://doi.org/10.1212/WNL.0b013e318224af8d
  55. Olde Dubbelink KT, Hillebrand A, Twisk JW, Deijen JB, Stoffers D, Schmand BA, Stam CJ, Berendse HW. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology. 2014;82:263-270. https://doi.org/10.1212/WNL.0000000000000034
  56. Caviness JN, Hentz JG, Belden CM, Shill HA, Driver-Dunckley ED, Sabbagh MN, Powell JJ, Adler CH. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson’s disease. Journal of Parkinsons Disease. 2015;5(1):117-124. https://doi.org/10.3233/JPD-140480
  57. Olde Dubbelink KT, Hillebrand A, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Berendse HW. Disrupted brain network topology in Parkinson’s disease: a longitudinal magnetoencephalography study. Brain. 137(1):197-207. https://doi.org/10.1093/brain/awt316
  58. Olde Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Hillebrand A, Berendse HW. Resting-state functional connectivity as a marker of disease progression in Parkinson’s disease: A longitudinal MEG study. Neuro Image Clinical. 2013;2:612-619. https://doi.org/10.1016/j.nicl.2013.04.003
  59. Seer C, Lange F, Georgiev D, Jahanshahi M, Kopp B. Event-related potentials and cognition in Parkinson’s disease: an integrative review. Neuroscience & Biobehavioral Reviews. 2016;71:691-714. https://doi.org/10.1016/j.neubiorev.2016.08.003
  60. Anang JB, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB. Dementia Predictors in Parkinson Disease: A Validation Study. Journal of Parkinson’s Disease. 2017;7(1):159-162. https://doi.org/10.3233/JPD-160925
  61. Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP. Prediction of cognition in Parkinson’s disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology. 2017;16(8):620-629. https://doi.org/10.1016/S1474-4422(17)30122-9
  62. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurology. 2010;9(12):1200-1213. https://doi.org/10.1016/S1474-4422(10)70212-X
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.